Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical.
Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines
Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding.
The collaborative effort harnesses Merck's expertise in immuno-oncology and Moderna's innovative mRNA technology to make a meaningful impact on patient outcomes.
Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 in combination with MSD s Keytruda in patients with resected high-risk.
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and…